Marcel W.
- Country
- Germany
- Department
- -
Research Overview
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
- Phase I Evaluation of MGY825 in Adults with Advanced Non-Small Cell Lung Cancer with or without NFE2L2/KEAP1/CUL3 Mutations
- Evaluation of Sotorasib (AMG 510) in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation: A Master Protocol Study
Data & Insights
Has run more than one trial at 172 of 374 partner sites.
Specializations
Advanced Non-Small Cell Lung Cancer
This investigator specializes in the treatment of advanced non-small cell lung cancer (NSCLC) with particular emphasis on various genetic mutations and targeted therapies.
- HER2 mutations
- EGFR mutations
- ALK-positive NSCLC
- MET mutations and amplifications
Research interests include novel therapeutic approaches for metastatic and unresectable NSCLC.
Small Cell Lung Cancer
The investigator conducts research in small cell lung cancer (SCLC) treatment, with specific focus on:
- Extensive-stage SCLC
- Relapsed SCLC
- Novel therapeutic interventions
Areas of investigation include innovative treatment approaches for pretreated extensive-stage SCLC.
Precision Medicine
Focus on biomarker-driven treatment approaches and molecular targeting in cancer therapy:
- KRAS p.G12C mutations
- TP53 Y220C mutations
- NFE2L2/KEAP1/CUL3 mutations
- Targeted therapy resistance
Expertise in developing personalized treatment strategies based on specific genetic alterations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.